このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ABVC BioPharma マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Uttam Patil

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.7%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

Mar 13

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Oct 05

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

Sep 23

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Aug 18

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

Aug 17

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

Jul 13

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

Jun 30

CEO（最高経営責任者

Uttam Patil (38 yo)

less than a year

在職期間

Dr. Uttam Yashwant Patil, Ph D., is Chief Executive Officer of ABVC BioPharma, Inc. from June 21, 2023. Dr. Patil has served as the Chief Operating and Scientific Officer of the BioKey, Inc. since May 2023...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Eugene Jiang	Chairman & Chief Business Officer	8.9yrs	US$200.00k	9.23% $ 734.1k
Uttam Patil	Chief Executive Officer	less than a year	データなし	0.67% $ 53.2k
Leeds Chow	CFO & Principal Accounting Officer	1.8yrs	US$180.00k	0.48% $ 38.2k
Tsung-Shann Jiang	Chief Scientific Officer	less than a year	US$200.00k	4.01% $ 319.4k

1.0yrs

平均在職期間

38yo

平均年齢

経験豊富な経営陣: ABVCの経営陣は経験豊富とはみなされません ( 1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Eugene Jiang	Chairman & Chief Business Officer	8.9yrs	US$200.00k	9.23% $ 734.1k
Tsung-Shann Jiang	Chief Scientific Officer	5.3yrs	US$200.00k	4.01% $ 319.4k
Tsang Ming Jiang	Director	6.6yrs	データなし	0.39% $ 30.9k
Norimi Sakamoto	Independent Director	6.6yrs	データなし	0.39% $ 30.8k
Yen-Hsin Chou	Independent Director	6.6yrs	データなし	0.39% $ 30.8k
Yoshinobu Odaira	Independent Director	5.3yrs	データなし	0.53% $ 42.5k
Susanna Cunningham-Rundles	Member of Scientific Advisory Board	no data	データなし	データなし
Chang-Jen Jiang	Director	6.6yrs	データなし	0.39% $ 30.8k
Che-Wei Hsu	Independent Director	2.1yrs	データなし	0.39% $ 30.7k
Shuling Jiang	Director	2.1yrs	データなし	8.06% $ 641.3k
Hsin-Hui Miao	Independent Director	2yrs	データなし	0.44% $ 35.3k
Yu-Min Chung	Independent Director	1.9yrs	データなし	0.39% $ 30.8k

5.3yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: ABVCの取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

ABVC BioPharma マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

Less than half of directors are independent

ABVC BioPharma, Inc. Announces Board Changes

Recent updates

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma, Inc. announced delayed 10-Q filing

Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study

ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.75 million.

ABVC BioPharma, Inc. announced that it expects to receive $1.75 million in funding

Nasdaq Grants ABVC Biopharma an Extension to Comply with Listing Rule 5550(b)(1)

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

ABVC BioPharma Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders' Equity Requirement

ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.20 loss in 1Q 2022)

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

ABVC BioPharma Receives an Additional 180 Days, Until August 14, 2023, to Comply with Rule 5550(a)(2)

Abvc Biopharma Abv-1505 Adhd Phase Iia Results Presented At 2023 Apsard Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma, Inc. Receives Thai FDA Approval for Phase II Vitargus Study Protocol

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder

ABVC BioPharma, Inc. Announces That Cedars-Sinai Medical Center Institutional Review Board (IRB) Approves Institution Joining the Phase I Study of ABV-1601

ABVC BioPharma, Inc. Announces Vitargus(R) Phase II Study Plan Approved by Hrec in Australia

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Abvc Biopharma, Inc. Provides Adhd Phase Ii Part 2 Clinical Study Update and Announces Ucsf Institutional Review Board Approval

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

ABVC BioPharma Receives Non-Compliance Letter from Nasdaq

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma, Inc. Announces Board Changes

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

ABVC BioPharma, Inc. Announces the Vitargus® Phase II Clinical Study Protocol Approval by the Central Research Ethics Committee (CREC) of the National Research Council of Thailand

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

ABVC BioPharma, Inc. Submitts Vitargus(R) Phase II Study Plan to Australia HREC

Abvc Biopharma, Inc. Appoints Ms. Hsin-Hui Miao to its Board

ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

ABVC BioPharma, Inc. Announces Board Elections

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $4.22 million.

ABVC BioPharma, Inc. Announces ADHD Phase II Part 2 Clinical Study First Subject

ABVC Biopharma Announces Streamlined Vitargus® Manufacturing Process

Insufficient new directors

ABVC BioPharma, Inc. Announces Vitargus Phase II Clinical Study Investigator Meeting

Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

ABVC BioPharma, Inc. Selects Additional Vitargus Phase II Study Sites

Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

High number of new directors

Third quarter 2021 earnings released: US$0.067 loss per share (vs US$0.095 loss in 3Q 2020)

High number of new directors

High number of new directors

High number of new directors

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

High number of new directors

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Second quarter 2021 earnings released: US$0.081 loss per share (vs US$0.095 loss in 2Q 2020)

High number of new directors

ABVC BioPharma, Inc. has completed a Composite Units Offering in the amount of $6.875 million.

マネジメント基準チェック /14